Component
Hericenone C
Species, preparation, dose and limitations are retained on linked claims.
3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Purified hericenones C, D and E failed to promote NGF gene expression in the 1321N1 assay that responded to the whole extract.
Experimental context and source evidence
- dose
- Purified hericenones C, D and E
- duration
- Acute
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Human 1321N1 astrocytoma cells
- limitations
- This source-specific null prevents assigning the extract's NGF induction to those three molecules; other assays may differ.
- nutrient_topic
- Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Hericenones and erinacines
- organism
- Human 1321N1 astrocytoma cells
- plain_language
- Purified hericenones C, D and E failed to promote NGF gene expression in the 1321N1 assay that responded to the whole extract.
- primary_references
- Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. (2008). https://pubmed.ncbi.nlm.nih.gov/18758067/ DOI: 10.1248/bpb.31.1727
- route
- In vitro
- tissue
- NGF gene expression
Hericenones & Erinacines: mechanism of action and interactions (2026-09-20) · lines 22–31
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human 1321N1 astrocytoma cells · source_derived_draft · unverified_draft
## hericenones-erinacines-hericenone-cde-null Purified hericenones C, D and E failed to promote NGF gene expression in the 1321N1 assay that responded to the whole extract. Model/species: Human 1321N1 astrocytoma cells Tissue/system: NGF gene expression Exposure: Purified hericenones C, D and E Route: In vitro Duration: Acute Limits: This source-specific null prevents assigning the extract's NGF induction to those three molecules; other assays may differ. Primary reference: Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. (2008). https://pubmed.ncbi.nlm.nih.gov/18758067/ DOI: 10.1248/bpb.31.1727 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
What acts on it
Lipase treatment removed the fatty-acid side chain of hericenone C to form deacylhericenone.
Experimental context and source evidence
- dose
- Hericenone C with lipase
- duration
- Incubation interval specified in the primary article
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Cell-free digestion followed by structural analysis
- limitations
- The preparation models possible metabolism but does not establish the responsible human digestive enzyme or in-vivo conversion fraction.
- nutrient_topic
- Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Hericenones and erinacines
- organism
- Cell-free digestion followed by structural analysis
- plain_language
- Lipase treatment removed the fatty-acid side chain of hericenone C to form deacylhericenone.
- primary_references
- Deacylated Derivative of Hericenone C Treated by Lipase Shows Enhanced Neuroprotective Properties Compared to Its Parent Compound. (2023). https://pubmed.ncbi.nlm.nih.gov/37299024/ DOI: 10.3390/molecules28114549
- route
- In vitro enzymatic treatment
- tissue
- Hericenone C deacylation
Hericenones & Erinacines: mechanism of action and interactions (2026-09-20) · lines 66–75
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Cell-free digestion followed by structural analysis · source_derived_draft · unverified_draft
## hericenones-erinacines-lipase-deacylation Lipase treatment removed the fatty-acid side chain of hericenone C to form deacylhericenone. Model/species: Cell-free digestion followed by structural analysis Tissue/system: Hericenone C deacylation Exposure: Hericenone C with lipase Route: In vitro enzymatic treatment Duration: Incubation interval specified in the primary article Limits: The preparation models possible metabolism but does not establish the responsible human digestive enzyme or in-vivo conversion fraction. Primary reference: Deacylated Derivative of Hericenone C Treated by Lipase Shows Enhanced Neuroprotective Properties Compared to Its Parent Compound. (2023). https://pubmed.ncbi.nlm.nih.gov/37299024/ DOI: 10.3390/molecules28114549 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
Where it participates (unsigned role)
Deacylhericenone produced greater BDNF mRNA expression and hydrogen-peroxide protection than parent hericenone C in 1321N1 cells.
Experimental context and source evidence
- dose
- Deacylhericenone versus hericenone C
- duration
- Acute
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Human 1321N1 astrocytoma cells
- limitations
- The comparison does not establish human absorption, brain exposure, or clinical neuroprotection.
- nutrient_topic
- Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Hericenones and erinacines
- organism
- Human 1321N1 astrocytoma cells
- plain_language
- Deacylhericenone produced greater BDNF mRNA expression and hydrogen-peroxide protection than parent hericenone C in 1321N1 cells.
- primary_references
- Deacylated Derivative of Hericenone C Treated by Lipase Shows Enhanced Neuroprotective Properties Compared to Its Parent Compound. (2023). https://pubmed.ncbi.nlm.nih.gov/37299024/ DOI: 10.3390/molecules28114549
- route
- In vitro
- tissue
- BDNF mRNA and cell protection
Hericenones & Erinacines: mechanism of action and interactions (2026-09-20) · lines 77–86
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human 1321N1 astrocytoma cells · source_derived_draft · unverified_draft
## hericenones-erinacines-deacylhericenone-activity Deacylhericenone produced greater BDNF mRNA expression and hydrogen-peroxide protection than parent hericenone C in 1321N1 cells. Model/species: Human 1321N1 astrocytoma cells Tissue/system: BDNF mRNA and cell protection Exposure: Deacylhericenone versus hericenone C Route: In vitro Duration: Acute Limits: The comparison does not establish human absorption, brain exposure, or clinical neuroprotection. Primary reference: Deacylated Derivative of Hericenone C Treated by Lipase Shows Enhanced Neuroprotective Properties Compared to Its Parent Compound. (2023). https://pubmed.ncbi.nlm.nih.gov/37299024/ DOI: 10.3390/molecules28114549 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.